A bill to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis.

Bill: 118-s-3220
Sponsor: full_name: Sen. Kelly, Mark [D-AZ]
Introduced: 2023-11-02
Policy area: Health
Latest action: action_date: 2023-11-02
text: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summaries:
action_date: 2023-11-02
action_desc: Introduced in Senate
text: <p>This bill expands the priority-review voucher program for tropical diseases to include coccidioidomycosis (also known as Valley fever). A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.</p>

tv_txt: II 118th CONGRESS 1st Session S. 3220 IN THE SENATE OF THE UNITED STATES November 2, 2023 Mr. Kelly (for himself and Ms. Sinema ) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions A BILL To expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis.

1. Expanding the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis Section 524(a)(3) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360n(a)(3) ) is amended— (1) by redesignating subparagraph (S) as subparagraph (T); and (2) by inserting after subparagraph (R) the following: (S) Coccidioidomycosis. .